Premium
Ganciclovir‐resistant cytomegalovirus encephalitis in a bone marrow transplant recipient
Author(s) -
Julin J.E.,
Van Burik J.H.,
Krivit W.,
Webb C.,
Holman C.J.,
Clark H.B.,
Balfour Jr. H.H.
Publication year - 2002
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1034/j.1399-3062.2002.02005.x
Subject(s) - foscarnet , ganciclovir , medicine , encephalitis , cytomegalovirus , virology , leukoencephalopathy , viremia , alemtuzumab , bone marrow , immunology , herpesviridae , pathology , human cytomegalovirus , transplantation , virus , viral disease , disease
A 20‐year‐old patient, who received a bone marrow transplant in order to treat metachromatic leukodystrophy (MLD), succumbed to cytomegalovirus (CMV) encephalitis. After CMV viremia developed, the patient received ganciclovir, but he was switched to foscarnet when ganciclovir resistance was suspected. Foscarnet was discontinued because of concern about its potential central nervous system toxicity. Autopsy samples of brain and cerebrospinal fluid contained CMV DNA with a UL97 mutation (M460V) known to confer ganciclovir resistance. No foscarnet resistance mutations were found.